Guard Therapeutics presents top-line results of Phase 2 (AKITA) study, 2023

Starting

Speaker: Tobias Agervald, CEO and Michael Reusch, CMO
Sector: Health care – Pharmaceuticals & Biotechnology
Activity: Audiocast with teleconference
Language: English

Annons